Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis

Trial Profile

Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Adalimumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Acronyms Complete-AS
  • Sponsors Abbott Laboratories; AbbVie
  • Most Recent Events

    • 13 Jul 2017 Planned number of patients changed from 1120 to 915.
    • 13 Jul 2017 Planned End Date changed from 1 Jun 2018 to 30 Nov 2019.
    • 13 Jul 2017 Planned primary completion date changed from 1 Jun 2018 to 30 Nov 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top